Abstract: A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen.

Abstract: The present invention concerns compositions and methods for using a &bgr;-adrenergic agonist for treating endometriosis, for treating infertility, and for improving fertility. The present invention further concerns formulating such a composition or method in such a way as to provide therapeutically sufficient levels of the &bgr;-adrenergic agonist locally while avoiding adverse systematic concentrations in the host, thereby minimizing or avoiding adverse side effects.

Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of vasculopathic, cardiac, central and peripheral cerebral disturbances and for the prevention of learning disorders or disorders related to ageing, as well as for coping with increased energy requirements, and which may take the form of a dietary supplement or an actual medicine in its own right, containing the following as its characterising active ingredients: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts; and (b) coenzyme Q10.

Abstract: Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.

Abstract: The present invention is directed to ion-sensitive, water-dispersible polymers. The present invention is also directed to a method of making ion-sensitive, water-dispersible polymers and their applicability as binder compositions. The present invention is further directed to fiber-containing fabrics and webs comprising ion-sensitive, water-dispersible binder compositions and their applicability in water-dispersible personal care products.

Abstract: Optically-activated particles for use in cosmetic preparations. The optically-activated particles include a plurality of substrate particles selected from the group consisting of nylons, acrylics, polyesters, other plastic polymers, natural materials, regenerated cellulose, metals and minerals; an optical brightener chemically bonded to each of the plurality of substrate particles to form integral units in the form of optically-activated particles for diffusing light to reduce the visual perception of skin imperfections, including cellulite, shadows, skin discolorations, and wrinkles; and each of the optically-activated particles are encapsulated with a UV transparent coating to increase the diffusion light to further reduce the visual perception of the skin imperfections.

Abstract: A composition of an aerosol coolant spray for killing and removing ticks from human skin, to be dispensed from a pressurized a pressurized aerosol spray cannister. The aerosol coolant spray composition includes a liquid coolant material for freezing the essential oil, and the cooled essential oil is used for immobilizing and killing the tick on the skin of a human. The aerosol coolant spray composition further includes a diluent material being used as a carrier material for emulsifying the essential oil and the coolant material within the pressurized aerosol spray cannister.

Abstract: An emulsion comprising: water; hydrophilic particles; and hydrophobic particles; wherein the hydrophilic and hydrophobic particles form shells encapsulating a gas that are suspended in the water, said shells comprising an external layer of hydrophilic particles and an internal layer of hydrophobic particles adjacent to the layer of hydrophilic particles.

Abstract: The invention provides methods of dermatological basic treatment including the steps of pre-treating the skin with a composition that comprises a mild anti-microbial agent, a buffer that adjusts the skin pH to slightly acidic and an agent that forms a protective layer on the skin. This basic treatment has the effect of extraordinarily mild cleansing and sanitizing, restoring lipids, and providing a protective coating to the skin. Basic treatment may be followed by appropriate dermatological therapy. The invention further provides suitable compositions to be used in the dermatological basic treatment.

Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations, as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.

Abstract: The present invention is a composition in the form of a soluble sheet or film which has a variety of uses, particularly in the personal care field. Such sheets are preferably water soluble. An important component of these water soluble sheets is a “base composition,” which includes a water soluble film forming polymer, a polyvinyl alcohol, and a humectant such as propylene glycol. Surfactant may be added to the liquid base composition so that, when the composition is dried into sheet form, the sheet will generate foam when exposed to water and have cleansing properties. Skin care ingredients may also be added to the base composition in addition to or in place of the surfactant. Volatile alcohols or hydrocarbons may also be incorporated into the liquid base composition to facilitate drying of the composition to form the flexible sheet product.

Abstract: The current invention is directed to methods of treating or preventing emphysema, pharmaceutical compositions suitable for the treatment or prevention of emphysema and methods for delivering formulations into the lung of a mammal suffering from emphysema. More generally, the invention encompasses the use of 13-cis-retinoic acid to treat or prevent certain chronic obstructive airway disorders, particularly chronic obstructive pulmonary disease including chronic bronchitis, emphysema and asthma in mammals, especially humans that smoke or smoked cigarettes. In another aspect, the present invention encompasses the use of pharmaceutical compositions of 13-cis-retinoic acid to treat emphysema. Moreover, the current invention encompasses the use of electrohydrodynamic aerosol devices, aerosol devices and nebulizers to deliver formulations of 13-cis-retinoic acid into the lung of a mammal suffering from emphysema. The invention also encompasses the systemic use as well as the local use of 13-cis-retinoic acid.

Abstract: A pharmaceutical composition comprising a solid carrier containing a liquid selected from the group consisting of a liquid active agent, a liquid enhancer, or a combination thereof.

Abstract: Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.

Abstract: An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaqlandin and one or more excipients.

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of: (a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.

Abstract: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1-60% by weight of trimethylated silica, b) from about 0.1-60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1-60% by weight of a nonvolatile oil having a viscosity of 200 to 1,000,000 centipoise at 25° C. d) 0.1-80% of a cosmetically acceptable carrier.

Abstract: This invention relates to a combination drug product comprising pioglitazone hydrochloride and a biguamide, e.g. metformin. In particular, the product comprises a core of the biguamide, e.g. metformin, at least a portion thereof has a layer or coat thereon of pioglitazone.

Abstract: A drug delivery system is provided including a bulk polymer phase and a polymeric drug-enriched phase within the bulk polymer phase. At least one drug is incorporated into the drug-enriched phase. The system can be used, for example, on implantable medical devices such as stents.

Abstract: A drug delivery device for delivering hormonal and other veterinary treatments intra-vaginally. A substance dispenser (21) is separate from the supporting device (20). The dispenser is in the form of drug impregnated gills or vanes (6, 7). In other aspects the drug may be dispensed by a micro-pump in the supporting device or the drug may be coated on the dispenser.